Advertisement

Heart and Vessels

, Volume 34, Issue 1, pp 29–32 | Cite as

Correction to: Association between plasma levels of PCSK9 and the presence of coronary artery disease in Japanese

  • Daisuke Nose
  • Yuhei Shiga
  • Yoko Ueda
  • Yoshiaki Idemoto
  • Kohei Tashiro
  • Yasusnori Suematsu
  • Takashi Kuwano
  • Ken Kitajima
  • Keijiro Saku
  • Shin-ichiro MiuraEmail author
Correction
  • 265 Downloads

Correction to: Heart and Vessels  https://doi.org/10.1007/s00380-018-1218-1

In the original publication of the article, Tables 1, 2 and 3 was published incorrectly. Unnecessary inequality symbols were added to all the numbers in the ‘p value’ of Tables 1, 2 and 3. The correct Tables 1, 2 and 3 should be as follows,
Table 1

Patient characteristics in all patients, non-CAD and CAD groups

 

All patients (n = 393)

Non-CAD group (n = 182)

CAD group (n = 211)

p value non-CAD vs. CAD

Age, years

66 (59–73)

63 (56–70)

69 (61–75)

< 0.0001

Sex male, % (n)

51 (202)

45 (82)

57 (120)

0.019

BMI, kg/m2

24 (22–26)

24 (22–26)

23 (21–26)

0.21

Family history, % (n)

26 (102)

24 (44)

27 (58)

0.46

Smoking, % (n)

38 (149)

33 (60)

42 (89)

0.061

HTN, % (n)

72 (283)

63 (115)

80 (168)

0.0003

DM, % (n)

23 (89)

16 (29)

28 (60)

0.003

DL, % (n)

67 (262)

62 (113)

71 (149)

0.074

CKD, % (n)

31 (124)

25 (46)

37 (78)

0.013

TG, mg/dl

117 (87–158)

109 (79–154)

124 (94–163)

0.017

LDL-C, mg/dl

115 ± 30

115 ± 30

114 ± 29

0.78

HDL-C, mg/dl

51 (44–62)

54 (45–66)

50 (43–59)

0.002

HbA1c, % (n)

5.7 (5.4–6.2)

5.7 (5.3–6.1)

5.9 (5.5–6.4)

0.0003

Fasting glucose, mg/dl

100 (93–113)

99 (93–107)

102 (93–121)

0.041

UA, mg/dl

5.4 (4.5–6.3)

5.4 (4.5–6.3)

5.4 (4.5–6.3)

0.93

eGFR, ml/min/1.73 m2

67 (57–77)

70 (60–80)

64 (55–75)

0.002

PCSK9, ng/ml

213 (169–268)

203 (156–257)

223 (172–278)

0.006

Log PCSK9

5.35 ± 0.36

5.29 ± 0.39

5.40 ± 0.33

0.004

Medication

    

 ARB, % (n)

38 (149)

31 (56)

44 (93)

0.007

 ACE-I, % (n)

3 (12)

2 (3)

4 (9)

0.12

 CCB, % (n)

36 (141)

27 (50)

43 (91)

0.001

 BB, % (n)

11 (43)

7 (12)

15 (31)

0.009

 Diuretic, % (n)

10 (41)

9 (17)

11 (24)

0.51

 Statin, % (n)

34 (134)

27 (50)

40 (84)

0.01

 SU, % (n)

9 (39)

7 (12)

13 (27)

0.037

 BG, % (n)

6 (24)

6 (11)

6 (13)

0.96

 DPP4-I, % (n)

11 (43)

8 (14)

14 (29)

0.052

Continuous variables are expressed as mean ± SD. When continuous variables did not show a normal distribution, the variables are expressed as a median value and interquartile range

CAD coronary artery disease, BMI body mass index, HTN hypertension, DM diabetes mellitus, DL dyslipidemia, CKD chronic kidney disease, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, HbA1c glycosylated hemoglobin A1c, UA uric acid, eGFR estimated glomerular filtration rate, PCSK9 pro-protein convertase subtilisin/kexin type 9, ARB angiotensin II receptor blocker, ACE-I angiotensin-converting enzyme inhibitor, CCB calcium channel blocker, BB beta-blocker, DU diuretic, SU sulfonylurea, BG biguanide, DPP4-I dipeptidyl-peptidase 4 inhibitor

Table 2

Patient characteristics of all patients, the patients with non-CAD and CAD in the non-statin and statin groups

 

Non-statin group (n = 259)

Statin group (n = 134)

All patients (n = 259)

Non-CAD group (n = 132)

CAD group (n = 127)

p value non-CAD vs. CAD

All patients (n = 134)

Non-CAD group (n = 50)

CAD group (n = 84)

p value non-CAD vs. CAD

Age, years

65 (58–73)

63 (55–70)

69 (60–75)

< 0.0001

67 (60–74)

64 (58–71)

69 (62–75)

0.059

Male, % (n)

52 (134)

45 (59)

59 (75)

0.021

51 (68)

46 (23)

54 (45)

0.40

BMI, kg/m2

23 (21–26)

24 (22–26)

23 (21–26)

0.22

24 (22–26)

24 (22–27)

24 (22–26)

0.39

Family history, % (n)

24 (63)

25 (33)

24 (30)

0.80

29 (39)

22 (11)

33 (28)

0.16

Smoking, % (n)

39 (102)

33 (44)

46 (58)

0.042

35 (47)

32 (16)

37 (31)

0.57

HTN, % (n)

67 (173)

60 (79)

74 (94)

0.016

82 (110)**

72 (36)

88 (74)

0.019

DM, % (n)

18 (47)

14 (18)

23 (29)

0.055

31 (42)**

22 (11)

37 (31)

0.072

DL, % (n)

49 (128)

48 (63)

51 (65)

0.58

100 (134)**

100

100

 

CKD, % (n)

31 (79)

24 (32)

37 (47)

0.026

34 (45)

26 (13)

37 (31)

0.19

TG, mg/dl

117 (87–158)

108 (79–154)

125 (96–162)

0.042

117 (90–163)

112 (78–156)

124 (93–166)

0.16

LDL-C, mg/dl

119 ± 30

117 ± 27

120 ± 32

0.362

107 ± 27**

110 ± 35

104 ± 23

0.27

HDL-C, mg/dl

51 (44–63)

53 (45–68)

49 (42–58)

0.005

52 (45–62)

54 (47–62)

51 (44–61)

0.31

HbA1c, %

5.7 (5.3–6.2)

5.6 (5.3–6.0)

5.8 (5.5–6.3)

0.002

5.9 (5.5–6.5)**

5.8 (5.6–6.3)

5.9 (5.5–6.8)

0.19

Fasting glucose, mg/dl

100 (93–112)

100 (94–108)

102 (93–118)

0.19

99 (93–116)

98 (92–105)

102 (93–127)

0.089

UA, mg/dl

5.4 (4.5–6.2)

5.3 (4.5–6.2)

5.4 (4.5–6.3)

0.61

5.6 (4.5–6.5)

5.7 (4.5–7.8)

5.5 (4.5–6.3)

0.22

eGFR, ml/min/1.73 m2

68 (57–78)

70 (61–82)

65 (55–76)

0.019

64 (57–75)

68 (59–77)

64 (55–73)

0.064

PCSK9, ng/ml

196 (159–247)

182 (150–235)

213 (169–261)

0.003

252 (201–303)**

252 (210–294)

253 (197–304)

0.67

Log PCSK9

5.28 ± 0.34

5.21 ± 0.36

5.35 ± 0.31

0.0008

5.49 ± 0.37**

5.51 ± 0.40

5.47 ± 0.34

0.51

CAD, % (n)

49 (127)

   

63 (84)*

   

VD 0

 

100 (132)

0

  

100

0

 

VD 1

 

0

45 (57)

  

0

32 (27)

 

VD 2 + 3

 

0

55 (70)

  

0

68 (57)

 

Gensini score

 

2.5 (0–6)

15 (10–23)

< 0.0001

 

2.5 (0–6)

18 (13–27)

< 0.0001

Medication

        

 ARB, % (n)

29 (76)

26 (33)

34 (43)

0.12

54 (73)**

46 (23)

60 (50)

0.13

 ACE-I, % (n)

2 (3)

2 (2)

2 (3)

0.62

5 (7)

2 (1)

7 (6)

0.17

 CCB, % (n)

31 (81)

23 (30)

40 (51)

0.002

45 (60)**

40 (20)

48 (40)

0.39

 BB, % (n)

8 (22)

7 (9)

10 (13)

0.32

16 (21)*

6 (3)

21 (18)

0.012

 Diuretic, % (n)

10 (27)

11 (14)

10 (13)

0.92

10 (14)

6 (3)

13 (11)

0.18

 SU, % (n)

7 (19)

6 (8)

9 (11)

0.42

15 (20)

8 (4)

19 (16)

0.071

 BG, % (n)

4 (11)

5 (6)

4 (5)

0.81

10 (13)

10 (5)

10 (8)

0.93

 DPP4-I, % (n)

9 (23)

8 (10)

10 (13)

0.45

15 (20)

8 (4)

19 (16)

0.071

Continuous variables are expressed as mean ± SD. When continuous variables did not show a normal distribution, the variables are expressed as a median value and interquartile range

CAD coronary artery disease, BMI body mass index, HTN hypertension, DM diabetes mellitus, DL dyslipidemia, CKD chronic kidney disease, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, HbA1c glycosylated hemoglobin A1c, UA uric acid, eGFR estimated glomerular filtration rate, PCSK9 pro-protein convertase subtilisin/kexin type 9, VD vessel disease (the number of significantly stenosed coronary vessels), ARB angiotensin II receptor blocker, ACE-I angiotensin-converting enzyme inhibitor, CCB calcium channel blocker, BB, beta-blocker, DU diuretic, SU sulfonylurea, BG biguanide, DPP4-I dipeptidyl-peptidase 4 inhibitor

*p < 0.05 vs. all patients in the non-statin group

**p < 0.01 vs. all patients in the non-statin group

Table 3

The univariable and multivariable logistic regression analysis regarding the association with CAD in all patients, the statin and non-statin groups

All patients

Variables

Univariable

Multivariable

OR

95% CI

p

OR

95% CI

p

Age

1.05

1.03–1.07

< 0.0001

1.05

1.02–1.08

< 0.0001

Male

1.61

0.42–0.92

0.020

2.10

1.21–3.65

0.007

BMI

0.96

0.90–1.01

0.12

0.92

0.86–0.99

0.021

Family history

1.19

0.75–1.87

0.45

1.34

0.80–2.24

0.26

Smoking

1.48

0.98–2.24

0.06

1.12

0.65–1.94

0.67

HTN

2.28

1.45–3.57

0.0003

1.62

0.95–2.75

0.075

DM

2.10

1.28–3.45

0.003

2.20

1.24–3.91

0.006

CKD

1.73

1.12–2.68

0.013

1.11

0.67–1.85

0.69

Log PCSK9

2.27

1.27–4.01

0.004

2.65

1.36–5.14

0.003

Statin

1.75

1.14–2.67

0.010

1.45

0.87–2.40

0.15

HDL-C

0.98

0.96–0.99

0.0005

0.98

0.96–0.99

0.008

LDL-C

1.00

0.99–1.01

0.78

1.01

1.00–1.01

0.18

Statin group

Variables

Univariable

Multivariable

OR

95% CI

p

OR

95% CI

p

Age

1.04

1.00–1.07

0.034

1.03

0.98–1.07

0.26

Male

1.35

0.67–2.73

0.40

1.44

0.52–3.98

0.48

BMI

0.37

0.057–2.43

0.30

0.88

0.77–1.00

0.047

Family history

1.77

0.79–3.98

0.16

2.24

0.89–5.62

0.078

Smoking

1.24

0.59–2.61

0.56

1.30

0.48–3.56

0.61

HTN

2.88

1.17–7.11

0.021

2.01

0.70–5.77

0.19

DM

2.07

0.93–4.63

0.068

3.31

1.24–8.84

0.013

CKD

1.66

0.78–3.69

0.20

1.46

0.57–3.75

0.43

Log PCSK9

0.72

0.27–1.91

0.51

0.66

0.22–1.98

0.45

HDL-C

1.00

0.97–1.02

0.69

0.99

0.96–1.02

0.60

LDL-C

0.99

0.98–1.02

0.27

0.99

0.98–1.01

0.37

Non-statin group

Variables

Univariable

Multivariable

OR

95% CI

p

OR

95% CI

p

Age

1.05

1.03–1.08

< 0.0001

1.07

1.04–1.11

< 0.0001

Male

1.78

1.09–2.92

0.021

3.03

1.46–6.29

0.002

BMI

0.95

0.89–1.02

0.15

0.91

0.83–1.00

0.049

Family history

0.93

0.53–1.64

0.8

1.04

0.53–2.02

0.91

Smoking

1.68

1.02–2.78

0.042

1.16

0.57–2.37

0.68

HTN

1.91

1.13–3.24

0.015

1.51

0.80–2.85

0.21

DM

1.87

0.98–3.58

0.054

1.65

0.76–3.57

0.20

CKD

1.84

1.07–3.14

0.027

0.91

0.47–1.75

0.77

Log PCSK9

3.65

1.67–7.99

0.0007

6.23

2.44–15.9

< 0.0001

HDL-C

0.97

0.95–0.99

0.0006

0.97

0.95–0.99

0.003

LDL-C

1.00

1.00–1.01

0.38

1.01

1.00–1.02

0.022

CAD coronary artery disease, OR odds ratio, CI confidence Interval, BMI body mass index, HTN hypertension, DM diabetes mellitus, CKD chronic kidney disease, PCSK9 pro-protein convertase subtilisin/kexin type 9, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol

Copyright information

© Springer Japan KK, part of Springer Nature 2018

Authors and Affiliations

  • Daisuke Nose
    • 1
  • Yuhei Shiga
    • 1
  • Yoko Ueda
    • 1
  • Yoshiaki Idemoto
    • 1
  • Kohei Tashiro
    • 1
  • Yasusnori Suematsu
    • 1
  • Takashi Kuwano
    • 1
  • Ken Kitajima
    • 1
  • Keijiro Saku
    • 1
    • 2
  • Shin-ichiro Miura
    • 1
    • 2
    Email author
  1. 1.Department of CardiologyFukuoka University School of MedicineFukuokaJapan
  2. 2.Department of Molecular Cardiovascular TherapeuticsFukuoka University School of MedicineFukuokaJapan

Personalised recommendations